Teva Pharmaceutical Industries Ltd. reported Tuesday that on a non-GAAP (generally accepted accounting principles) basis, it earned $1.1 billion net profit in the fourth quarter of 2010, or $1.25 in earnings per share.
The figure was below the consensus analysts estimate of $1.28 per share.
Teva reported record full year net sales of $16.1 billion for 2010, up 16 percent, compared to 2009.
Fourth quarter revenue was a record $4.4 billion, up 16%, compared to the fourth quarter of 2009.
The pharmaceuticals company reported record global in-market sales of its multiple-sclerosis drug Copaxone of $938 million in the fourth quarter, up 26% compared to the fourth quarter of 2009.
For the full year of 2010, non-GAAP net profit was $4.1 billion ($4.54 per share). Net profit was 36% higher than in 2009, and the EPS figure was 35% higher than in 2009. On a GAAP basis, net profit was $3.3 billion ($3.67 per share).